Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

985197aad1d7d9e9289657be.12loLFHRCqBgSWag1_dbCExM_91LbYHJyFYNzlmoHYs.hR8QFGSeOMQQLjDpo6cpSzQ5lasCC8eGozs8th3pR9y7OT19ZZo64QsYIw~29a1217ee4f88cb9057f8f7f767d6fd1
07-14 Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206 MT
07-13 Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating MT
07-13 Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… Zonebourse
07-08 BofA Securities Adjusts Biogen Price Target to $217 From $203 MT
07-08 Morgan Stanley Adjusts Price Target Biogen to $222 From $224, Maintains Equalweight Rating MT
07-07 RBC Capital Adjusts Biogen Price Target to $242 From $227, Maintains Outperform Rating MT
07-07 Jefferies Adjusts Price Target on Biogen to $255 From $210 MT
07-07 Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two… Zonebourse
07-06 HSBC Adjusts Price Target on Biogen to $157 From $150 MT
06-29 Needham Adjusts Price Target on Biogen to $256 From $255, Maintains Buy Rating MT
06-18 Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says MT
06-18 Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating MT
06-15 Mizuho Trims Price Target on Biogen to $221 From $236, Keeps Outperform Rating MT
06-08 Needham Upgrades Biogen to Buy From Hold, Price Target is $255 MT
05-27 RBC Lifts Price Target on Biogen to $227 From $222, Keeps Outperform Rating MT
05-15 Piper Sandler Adjusts Price Target on Biogen to $225 From $214, Maintains Overweight Rating MT
05-14 Oppenheimer Raises Biogen Price Target to $300 From $275, Maintains Outperform Rating MT
05-01 Citigroup Adjusts Biogen Price Target to $200 From $190 MT
04-30 Goldman Sachs Adjusts Biogen Price Target to $250 From $238 MT
04-30 Guggenheim Adjusts Price Target on Biogen to $260 From $246 MT
04-30 Goldman Sachs Adjusts Price Target on Biogen to $250 From $238 MT
04-30 Bernstein Adjusts Price Target on Biogen to $200 From $201 MT
04-30 Rothschild & Co Redburn Adjusts Price Target on Biogen to $190 From $180 MT
04-30 Morgan Stanley Adjusts Price Target on Biogen to $206 From $200 MT
04-29 Wedbush Raises Price Target on Biogen to $196 From $191 as 'Catalyst Engine Revving Up', Keeps Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+9.86%
+21.06%
+20.33%
+47%
+12.23%
-21.93%
-2.93%
+32.1%
+7.12%
+28.75%
Average +15.36%
Weighted average by Cap. +17.72%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
205.99USD
Average target price
226.29USD
Spread / Average Target
+9.86%
High Price Target
300.00USD
Spread / Highest target
+45.64%
Low Price Target
157.00USD
Spread / Lowest Target
-23.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Cantor Fitzgerald
Wedbush
BofA Securities
Morgan Stanley
RBC Capital Markets
Jefferies & Co.
HSBC
Needham & Co.
Mizuho Securities
Piper Sandler
Oppenheimer
Citigroup
Goldman Sachs
Guggenheim
Bernstein
Rothschild & Co Redburn
JPMorgan Chase
UBS
Wells Fargo Securities
HC Wainwright
Canaccord Genuity
TD Cowen
Stifel Nicolaus
BMO Capital
Baird
Truist Securities
Argus
Scotiabank
Redburn Atlantic
Leerink Partners
Barclays
Raymond James
Atlantic Equities
Cowen
SVB Securities LLC
SVB Leerink
William Blair & Co.
Credit Suisse
DZ Bank
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
205.99USD
Average target price
226.29USD
Spread / Average Target
+9.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BIIB Stock
  4. Consensus Biogen Inc.